Department of Medical Microbiology and Immunology, Coccidioidomycosis Serology Laboratory, University of California, Davis, 1 Shields Avenue, Tupper Hall, Davis, CA 95616, USA.
Mycopathologia. 2010 Nov;170(5):291-313. doi: 10.1007/s11046-010-9324-3. Epub 2010 Jun 5.
Isavuconazole is a new triazole currently undergoing phase III clinical trials. This compound has shown in vitro activity against a large number of clinically important yeasts and moulds including Aspergillus spp., Fusarium spp., Scedosporium spp., Candida spp., the Zygomycetes and Cryptococcus spp. Similar to voriconazole, reduced in vitro activity is seen against Histoplasma capsulatum. In vivo efficacy has been demonstrated in murine models of invasive aspergillosis and candidiasis. Additionally, there are several potential pharmacokinetic and drug-drug interaction advantages of this compound over existing antifungal agents. This review summarizes existing data that has been either published or presented at international symposia.
伊曲康唑是一种新的三唑类药物，目前正在进行 III 期临床试验。该化合物在体外对许多重要的临床酵母和霉菌具有活性，包括曲霉菌属、镰刀菌属、枝孢菌属、念珠菌属、接合菌属和隐球菌属。与伏立康唑类似，对荚膜组织胞浆菌的体外活性降低。在侵袭性曲霉病和念珠菌病的小鼠模型中已证实其具有体内疗效。此外，与现有抗真菌药物相比，该化合物具有多种潜在的药代动力学和药物相互作用优势。本综述总结了已发表或在国际研讨会上报告的现有数据。
